What Biotech Can Teach Us About Long Duration Investing

Every investor in long-duration, capital-intensive sectors eventually faces the same question: what do you do when the exit markets close and your companies still need years of funding? Keith Crandell answered it the hard way. His firm, ARCH Venture Partners, started as a University of Chicago experiment with a $9 million fund that took 15 months to raise, then hit biotech's "nuclear winter,"…